Antonio Ahn

Peter MacCallum Cancer Centre — Australia

Medicine · Health Sciences

13h-index605citations53works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(29), Advanced Breast Cancer Therapies(27), Microtubule and mitosis dynamics(18), Cancer Immunotherapy and Biomarkers(7), Epigenetics and DNA Methylation(6)

Publications53 total

Abstract GS3-06: Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer
Clinical Cancer Research·2026
Correction: INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Cancer Discovery·2025Open Access
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Intracellular zinc protects tumours from T cell-mediated cytotoxicity
Cell Death and Differentiation·2024· 7 citedOpen Access
The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects
Immunity·2024· 23 citedOpen Access
Abstract LT02: Regulation of Exhausted CD8+ T cell Differentiation by IKZF Transcription Factors
Cancer Research·2024· 1 cited
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024· 1 citedOpen Access
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Data from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024· 3 citedOpen Access
Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 6 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Shom Goel(30), Krutika Ambani(29), Catherine Dietrich(27), Michael Taylor(27), Kun‐Hui Lu(27), Catherine Blyth(27), Rhiannon Coulson(27), Susanne Ramm(27), Alec Trub(26), Keefe T. Chan(26), Christabella A. Mahendra(26), April C. Watt(26), Sunil Kumar Matsa(26), John Bisi(26), Jay C. Strum(26), Patrick J. Roberts(26), Michael R. Eccles(17), Aniruddha Chatterjee(13), Peter A. Stockwell(11), Euan J. Rodger(10)